TA Ventures portfolio company Gameto secures $33M in series B funding to advance novel in vitro fertilization treatments.

The fresh capital will primarily support the clinical development of Fertilo, an investigational in vitro maturation (IVM) solution that utilizes engineered ovarian support cells (OSCs) to mature eggs outside the body. This innovative approach aims to replace traditional hormonal injections, reducing the in vitro fertilization (IVF) and egg-freezing process from 10-14 days to just 2-3 days.

Gameto has received tentative approval from the U.S. Food and Drug Administration to proceed to Phase 3 trials, pending the completion of certain assay and manufacturing requirements. The funding will also support Fertilo’s commercial launch in Australia and Latin America, where it is already being used clinically.